Date: 2016-09-01
Type of information: Financing round
Company: OncoDNA (Belgium)
Investors: IPG/bio.be (Belgium) Invest4OncoDNA (Belgium) Sambrinvest (Belgium) Vinsovier (Belgium) Sofinim NV (Belgium) SRIW (Belgium) CPH (Belgium) Inventures (USA - CA)
Amount: € 7.7 million
Funding type: financing round
Planned used: The funds will be used by OncoDNA to speed up its international growth , develop its innovative SaaS (Software as a OncoDNA strives to obtain the reimbursement for its portfolio of services including: (1) OncoDEEP (a combination of DNA sequencing and protein analyses of solid biopsies for an enlightened treatment decisionmaking),
Service) platform, and further expand its reference network of oncologists around the world.
The Belgium-based company offers cutting-edge, high standard solutions and aims to provide oncologists with the most accurate treatment options to guide them from molecular tumour profiling (OncoDEEP) to personalised liquid biopsy (OncoTRACE). These solutions help oncologists in their therapeutic choice with drug treatment options and treatment efficacy monitoring.
(2) OncoDEEP&TRACE which combines analyses on both the solid tumour and the liquid biopsy for the very first time, and (3) OncoTRACE, the first personalised liquid biopsy analysing cell-free circulating tumour DNA to
monitor cancer evolution.
The company also intends to pursue the development of its IT platforms with the launch of OncoKDM, a SaaS (Software as a Service) platform linked to OncoSHARE and to increase the size of OncoDNA’s patient database. This will be achieved through clinical studies and scientific collaborations with academia and pharmaceutical companies.
Others: * On September 1, 2016, OncoDNA, a Belgium-based company founded three years ago, announced the closing of equity financing at € 7.7 million. The new shares were subscribed for by both the historical shareholders (IPG/bio.be, Invest4OncoDNA, Sambrinvest, and Vinsovier) as well as a group of four new investors (Sofinim NV, an affiliate of Ackermans & van Haaren, SRIW, CPH, and Inventures). Post-capital increase, Ackermans & van Haaren will hold a
15% participation in the company.
OncoDNA has developed an innovative reporting, sharing, and networking platform, OncoSHARE, that now hosts the largest cancer community of oncologists, patients, and relatives with approximately 10,000 people using it.
Therapeutic area: Cancer - Oncology
